Evaluation of hepatitis B vaccine responsiveness in ‎hemodialysis and peritoneal dialysis patients

Salama Elsayed Farag, Tarek A. Ghonemy, Sameh A. Soliman, Ahmed Bihery


Background: Hepatitis B Virus (HBV) infection is considered as a major cause of liver cirrhosis and hepatocellular carcinoma. Patients with End Stage Renal Disease (ESRD) are a risk group for HBV infection. The vaccine of hepatitis B has been recommended for prevention of HBV infection in ESRD patient especially on renal replacement therapy.  

Methods: Eighty seven patients with ESRD on peritoneal ‎dialysis and hemodialysis requiring primary hepatitis B vaccination were ‎enrolled in the study. Each of them received 40 µg of recombinant hepatitis B ‎vaccine in a four-dose schedule. Antibody response was determined by the ‎levels of antibodies to the hepatitis B surface antigen (anti-HBs) after last ‎doses of the vaccination schedule.  

Results: We observed three response patterns to the immunizations in all patients after vaccination, the nonresponders (24.7%) never reached the minimum protective titer of 10 mIU/mL, the poor responders (18.5%) had titers between 10 and 100 mIU/mL, and the good responders (56.8%) had antibody titers above 100 mIU/mL. Despite a reduction in anti-HBs over time, the good responders did not become unprotected during the observation period, especially those participants who had titers above 1000 mIU/mL after the initial immunization.  

Conclusions: We concluded that the immune ‎response of the HBV vaccine was reduced in the HD and PD patients, which ‎need yearly re-evaluation of seroconversion with booster doses of HBV ‎vaccination if needed‎.



End stage renal disease, Hepatitis B virus, Vaccine

Full Text:



Alter MJ, Arduino MJ, Lyerla HC, Miller ER, Tokars JI. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43.

Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12(3):378-82.

Chau KF, Cheng YL, Tsang DN, Choi KS, Wong KM, Chak WL, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis. 2004;43:910-7.

Goodman W, Gallagher N, Sherrard D. Peritoneal dialysis fluid as a source of hepatitis antigen. Nephron. 1981;29:107-9.

O’Connor J. Priorities for immunization against hepatitis. Br Med J. 1982;284:1876.

Drachman R, Isacsohn M, Rudensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant. 1989;4:372-4.

Ozener C, Fak AS, Avsar E, Cınar S, Lawrence R, Akoglu E. The effect of alpha interferon therapy and short interval intradermal administration on response to hepatitis B vaccine in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1339-40.

Center for Disease Control (CDC). Outbreaks of hepatitis B virus infection among hemodialysis patients, California, Nebraska, and Texas, 1994. MMWR. 1996;45:285-9.

Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol. 2012;13:97.

Pin M, Compte MT, Angelet P, Gállego C, Gutiérrez C, Martinez Vea A. Long-term evaluation of immune response to hepatitis B vaccine in 136 patients undergoing hemodialysis. Nefrologia. 2009;29(5):415-20.

Mauri JM, Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant. 1997;12:729-32.

El-Reshaid K, Al-Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine. 1994;12:223-8.

Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis. 1991;11(2):73-83.

Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine. 2004;22:3963-7.

Peces R, De la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in the hemodialysis patients. Am J Kidney Dis. 1997;29:239-45.

Cheng CH, Huang CC, Leu ML, Chiang CYF, Wu MS, Lai PC. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine. 1997;15(12-13):1353-7.

Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16:95-7.

Swan AM, DeVita MV. Higher response rate to hepatitis B vaccination observed in chronic hemodialysis patients. Clin Nephrol. 1997;47(3):207-8.

Radovic MM, Ostric V, Djukanovic L. Complete seroconversion after vaccination against hepatitis B virus in hemodialysis patients. Clin Nephrol. 1997;47(3):206-9.

Kroes AC, van Bommel EF, Kluytmans JA, Weimar W. Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of Bloodborne viruses. Infect Control Hosp Epidemiol. 1998;19(7):508-10.